Annovis Bio, Inc. (ANVS) Bundle
A Brief History of Annovis Bio, Inc.
Founded in 2008, Annovis Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, specifically Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company has made significant strides in advancing its drug candidates through various clinical stages, although it has yet to generate revenue from product sales.
Clinical Development and Trials
As of September 30, 2024, Annovis Bio has been engaged in multiple clinical trials, most notably its Phase 3 study in patients with PD and a Phase 2/3 study in AD. The company’s lead compound, ANVS401, is designed to inhibit neurotoxic proteins associated with these diseases.
During 2024, Annovis Bio wound down activities for its completed studies, which resulted in substantial reductions in operational expenditures. Research and development expenses for the nine months ended September 30, 2024, totaled $15.0 million, down from $29.9 million for the same period in 2023, showcasing a decrease of $14.9 million attributed primarily to reduced contract research expenditures.
Financial Performance
Throughout its history, Annovis Bio has reported consistent net losses, reflecting its investment in research and development without immediate returns. The reported net loss for the nine months ended September 30, 2024, was $18.7 million, compared to $33.99 million for the same period in 2023, indicating a year-over-year improvement of $15.3 million.
Stock Performance and Financing Activities
As of September 30, 2024, Annovis Bio had approximately 13.3 million shares of common stock outstanding. The company's stock has experienced volatility, influenced by its clinical trial results and market conditions. The exercise price of its Canaccord Warrants is set at $9.00.
To support its operations, Annovis Bio has engaged in various financing activities, including an Equity Line of Credit (ELOC) Purchase Agreement announced on April 25, 2024. This agreement allows the company to sell up to 2,051,428 shares of common stock, providing a critical funding source.
| Financial Metrics | 2024 (9M) | 2023 (9M) | Change |
|---|---|---|---|
| Research and Development Expenses | $15.0 million | $29.9 million | ($14.9 million) |
| Net Loss | $18.7 million | $33.99 million | ($15.3 million) |
| Cash and Cash Equivalents (as of Sept 30, 2024) | $12.6 million | N/A | N/A |
Future Outlook
Looking ahead, Annovis Bio plans to continue its efforts in developing and seeking regulatory approvals for its product candidates. The company anticipates raising additional capital to support its ongoing clinical trials and operations. This funding will be crucial as it prepares to initiate its pivotal Phase 3 studies for AD and PD in early 2025, with expectations of substantial expenditures associated with these developments.
A Who Owns Annovis Bio, Inc. (ANVS)
Shareholder Structure
As of September 30, 2024, Annovis Bio, Inc. had a total of 13,283,667 shares of common stock issued and outstanding.
Major Shareholders
| Shareholder Type | Name | Shares Held | Percentage Ownership |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 1,200,000 | 9.0% |
| Institutional Investor | The Vanguard Group, Inc. | 900,000 | 6.8% |
| Individual Investor | Dr. Maria L. Maccecchini (CEO) | 500,000 | 3.8% |
| Individual Investor | Board Members (Various) | 300,000 | 2.3% |
Management Ownership
Management, including executive officers and directors, collectively owned approximately 15% of the total shares outstanding as of September 30, 2024.
Recent Stock Transactions
In the first nine months of 2024, Annovis Bio raised approximately $12.5 million through various equity offerings, including a registered direct offering and an equity line of credit (ELOC).
Stock Performance
The closing stock price of Annovis Bio on September 30, 2024, was $8.06. The stock has experienced significant volatility, with a high of $18.70 earlier in the year.
Warrant and Derivative Liabilities
As of September 30, 2024, the company had outstanding warrants with an exercise price of $9.00. The fair value of these warrants was estimated to be approximately $1.5 million.
Recent Financing Activities
- On April 25, 2024, Annovis Bio entered into an ELOC Purchase Agreement to sell up to 2,051,428 shares.
- In March 2024, the company completed a registered direct offering for net proceeds of approximately $3.9 million.
Summary of Financial Condition
As of September 30, 2024, Annovis Bio reported total assets of $14.4 million and total liabilities of $7.3 million. The accumulated deficit stood at approximately $129 million.
Board of Directors
The Board of Directors includes individuals with significant experience in biotechnology and pharmaceuticals, contributing to the strategic direction of the company.
Annovis Bio, Inc. (ANVS) Mission Statement
Company Overview
Annovis Bio, Inc. (NASDAQ: ANVS) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). The company aims to address significant unmet medical needs through innovative research and development.
Mission Statement
The mission of Annovis Bio is to develop and commercialize therapies that significantly improve the quality of life for patients suffering from neurodegenerative diseases, thereby transforming the treatment landscape for these debilitating conditions.
Core Values
- Innovation: Commitment to cutting-edge research to develop effective treatments.
- Patient-Centric: Focus on the needs and well-being of patients.
- Integrity: Upholding the highest ethical standards in all operations.
- Collaboration: Building partnerships with stakeholders including patients, healthcare professionals, and research institutions.
Strategic Goals
Annovis Bio aims to achieve the following strategic goals:
- Advance clinical trials for its lead product candidate, ANVS401, which targets neurodegenerative diseases.
- Expand research on the effects of its therapies on neurotoxic proteins associated with AD and PD.
- Enhance shareholder value through successful product development and commercialization.
Financial Overview
As of September 30, 2024, Annovis Bio reported the following financial data:
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $12,638,357 | $14,716,616 | $2,078,259 |
| Research and Development Expenses | $2,689,561 | $13,837,650 | ($11,148,089) |
| General and Administrative Expenses | $1,698,050 | $1,025,621 | $672,429 |
| Total Operating Expenses | $4,387,611 | $14,863,271 | ($10,475,660) |
| Cash and Cash Equivalents | $12,636,630 | $6,354,942 | $6,281,688 |
Recent Developments
In 2024, Annovis Bio has made significant progress in its clinical trials. The company is currently focused on the following:
- Completion of a pivotal Phase 3 study for Alzheimer's Disease expected to commence in early 2025.
- Expansion of its drug development pipeline, specifically targeting neurotoxic proteins.
- Engagement with regulatory agencies to facilitate the approval process for its therapies.
Funding and Capital Resources
Annovis Bio has financed its operations primarily through the sale of common stock and warrants. As of September 30, 2024, the company reported an accumulated deficit of $128,984,803. The company has also entered into an ELOC Purchase Agreement allowing for the sale of shares to meet ongoing financial needs.
| Funding Source | Net Proceeds (2024) |
|---|---|
| ELOC Purchase Agreement | $8,600,000 |
| Registered Direct Offerings | $3,900,000 |
| Warrant Exercises | $8,025,003 |
Market Position
Annovis Bio operates in a competitive landscape with a focus on neurodegenerative diseases. The company is positioned to leverage its innovative therapies to capture market share in a sector that is increasingly prioritizing effective treatments for conditions like Alzheimer's and Parkinson's diseases.
Conclusion
Through its mission and strategic initiatives, Annovis Bio, Inc. continues to work towards making a meaningful impact in the lives of patients suffering from neurodegenerative diseases, while navigating the complexities of clinical development and market dynamics.
How Annovis Bio, Inc. (ANVS) Works
Company Overview
Annovis Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). The company’s lead product candidate, ANVS401, targets neurotoxic proteins implicated in these diseases.
Financial Performance
As of September 30, 2024, Annovis reported the following financial metrics:
| Metric | Amount (in thousands) |
|---|---|
| Cash and Cash Equivalents | $12,636 |
| Total Assets | $14,362 |
| Total Liabilities | $7,298 |
| Accumulated Deficit | $(128,985) |
| Net Loss for the Quarter | $(12,638) |
| Net Loss for Nine Months | $(18,726) |
Operating Expenses
For the three months ended September 30, 2024, operating expenses were as follows:
| Expense Type | Amount (in thousands) |
|---|---|
| Research and Development | $2,690 |
| General and Administrative | $1,698 |
| Total Operating Expenses | $4,388 |
For the nine months ended September 30, 2024, the operating expenses were:
| Expense Type | Amount (in thousands) |
|---|---|
| Research and Development | $14,997 |
| General and Administrative | $4,963 |
| Total Operating Expenses | $19,960 |
Cash Flows
For the nine months ended September 30, 2024, the cash flows were as follows:
| Cash Flow Type | Amount (in thousands) |
|---|---|
| Net Cash Used in Operating Activities | $(13,609) |
| Net Cash Provided by Financing Activities | $20,491 |
| Net Increase in Cash and Cash Equivalents | $6,882 |
Clinical Development
Annovis is currently winding down activities related to completed Phase 3 studies in early PD patients and Phase 2/3 in AD patients. The company expects to initiate a pivotal Phase 3 study for AD in the first quarter of 2025.
Stock Performance
As of September 30, 2024, the company had 13,283,667 shares issued and outstanding. The stock price was approximately $8.06 at that time. The company has a history of warrant exercises and stock option grants, reflecting its ongoing equity financing efforts.
Funding Requirements
Annovis has indicated a need for additional capital to fund operations over the next 12 months. The company has entered into an ELOC Purchase Agreement, which allows it to sell up to 2,051,428 shares of common stock to meet its cash needs.
| Funding Source | Details |
|---|---|
| ELOC Purchase Agreement | Up to 2,051,428 shares; commitment to purchase shares to fund operations |
| Registered Direct Offerings | Net proceeds of $3.9 million from March offerings |
| Private Placements | Net proceeds of $1.1 million from April 2023 placement |
Recent Developments
In the third quarter of 2024, Annovis reported a significant loss of $7.9 million due to changes in the fair value of warrants. The company continues to evaluate its clinical pipeline and adjust its strategy to manage costs effectively.
How Annovis Bio, Inc. (ANVS) Makes Money
Business Model Overview
Annovis Bio, Inc. (ANVS) primarily engages in the development of therapeutic solutions for neurodegenerative diseases, specifically focusing on Alzheimer's Disease (AD) and Parkinson's Disease (PD). The company has not yet generated revenue from product sales, relying heavily on financing strategies to fund its operations and clinical trials.
Revenue Generation Strategies
As of 2024, Annovis Bio has not generated any revenue from product sales. Instead, it focuses on funding its operations through:
- Public and private equity offerings
- Debt financings
- Collaboration and licensing arrangements
- Sales of common stock and warrants
Financial Performance
For the nine months ended September 30, 2024, Annovis reported the following financial figures:
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Loss | $(18,726) | $(33,991) |
| Total Operating Expenses | $19,960 | $34,593 |
| Research and Development Expenses | $15,000 | $29,886 |
| General and Administrative Expenses | $4,963 | $4,707 |
| Interest Income | $206 | $602 |
Funding Activities
During the nine months ended September 30, 2024, Annovis raised funds through various financing activities:
| Activity | Amount (in thousands) |
|---|---|
| Proceeds from issuance of common stock | $12,466 |
| Proceeds from exercise of warrants | $8,025 |
| Proceeds from exercise of stock options | — |
Stockholder's Equity and Capital Structure
As of September 30, 2024, Annovis had the following stockholder equity metrics:
| Metric | Value (in thousands) |
|---|---|
| Cash and Cash Equivalents | $12,637 |
| Accumulated Deficit | $(128,985) |
| Total Stockholders' Equity (Deficit) | $7,064 |
Research and Development Focus
Annovis has dedicated significant resources to research and development:
- Phase 3 Study in Parkinson's Disease: The company is currently conducting a Phase 3 study targeted at early PD patients.
- Phase 2/3 Study in Alzheimer's Disease: Aimed at addressing unmet medical needs for AD.
Recent Developments
In April 2024, Annovis entered into an Equity Line of Credit (ELOC) Purchase Agreement, allowing the company to sell up to 2,051,428 shares of common stock. As of September 30, 2024, approximately 1.2 million shares had been sold under this agreement for net proceeds of $8.6 million.
Stock Options and Warrants
As of September 30, 2024, the company had:
- 1,877,751 stock options outstanding
- 2,400 warrants outstanding
The exercise price for the Canaccord Warrants is $9.00 per unit, with a redemption option contingent on specific stock performance metrics.
Annovis Bio, Inc. (ANVS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Annovis Bio, Inc. (ANVS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Annovis Bio, Inc. (ANVS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Annovis Bio, Inc. (ANVS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.